UP!
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-02 | Future report Set alerts | |
| Q2 2022 | 2022-08-04 | -0.53 | -0.53 |
| Q1 2022 | 2022-05-05 | -0.32 | -0.32 |
| Q4 2021 | 2022-03-08 | 1.67 | 1.67 |
| Q3 2021 | 2021-11-04 | -0.51 | -0.51 |
| Q2 2021 | 2021-08-05 | -0.31 | -0.31 |
| Q1 2021 | 2021-05-06 | -0.70 | -0.70 |
| Q4 2020 | 2021-03-10 | 1.32 | 1.32 |
| Q3 2020 | 2020-11-05 | -0.10 | 0.00 |
| Q2 2020 | 2020-08-06 | -0.33 | -0.33 |
| 2016-05-05 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-03-12 | Reiterated Rating | Piper Jaffray | Hold | |
| 2016-03-12 | Reiterated Rating | Piper Jaffray Cos. | Hold | |
| 2016-03-11 | Reiterated Rating | Wedbush | Outperform | $6.00 to $3.00 |
| 2016-03-11 | Reiterated Rating | RBC Capital | Sector Perform | $2.00 |
| 2016-03-11 | Reiterated Rating | Royal Bank Of Canada | Sector Perform | $2.00 |
| 2016-01-04 | Reiterated Rating | Wedbush | Outperform | $6.00 |
| 2015-12-08 | Reiterated Rating | Wedbush | Buy | |
| 2015-12-02 | Reiterated Rating | Wedbush | Outperform | $6.00 |
| 2015-11-18 | Reiterated Rating | Wedbush | Buy | $6.00 |
| 2015-11-11 | Reiterated Rating | Cowen and Company | Market Perform | |
| 2015-11-06 | Reiterated Rating | Piper Jaffray | Neutral | $1.50 to $1.80 |
| 2015-11-06 | Boost Price Target | Jefferies Group | Hold | $1.00 to $1.50 |
| 2015-10-26 | Reiterated Rating | Wedbush | Buy | $6.00 |
| 2015-10-02 | Reiterated Rating | Wedbush | Outperform | $11.00 to $6.00 |
| 2015-10-02 | Reiterated Rating | RBC Capital | Sector Perform | $2.00 |
| 2015-09-15 | Reiterated Rating | Wedbush | Outperform | |
| 2015-09-15 | Reiterated Rating | Deutsche Bank | Sell | |
| 2015-09-15 | Reiterated Rating | Deutsche Bank AG | Sell | |
| 2015-08-05 | Reiterated Rating | Wedbush | Buy | $13.00 to $11.00 |
| 2015-07-23 | Downgrade | Jefferies Group | Buy to Hold | |
| 2015-07-22 | Downgrade | Ladenburg Thalmann | Buy to Neutral | |
| 2015-07-22 | Downgrade | RBC Capital | Outperform to Sector Perform | $8.00 to $2.00 |
| 2015-07-22 | Reiterated Rating | Wedbush | Buy | $13.00 |
| 2015-07-22 | Downgrade | Cowen and Company | Outperform to Market Perform | |
| 2015-07-22 | Downgrade | Piper Jaffray | Overweight to Neutral | |
| 2015-07-17 | Reiterated Rating | RBC Capital | Outperform | $8.00 |
| 2015-07-17 | Reiterated Rating | Piper Jaffray | Overweight | $8.00 |
| 2015-07-10 | Reiterated Rating | Cowen and Company | Buy | |
| 2015-07-07 | Reiterated Rating | Wedbush | Outperform | $17.00 |
| 2015-06-29 | Downgrade | Susquehanna | Positive to Neutral | |
| 2015-05-28 | Set Price Target | Wedbush | Buy | $17.00 |
| 2015-05-05 | Reiterated Rating | Credit Suisse | Neutral | $5.00 |
| 2015-05-05 | Reiterated Rating | Credit Suisse Group AG | Neutral | $5.00 |
| 2015-03-12 | Upgrade | Ladenburg Thalmann | Neutral to Buy | |
| 2015-03-09 | Boost Price Target | Wedbush | Outperform | $14.00 to $17.00 |
| 2014-11-10 | Downgrade | Ladenburg Thalmann | Buy to Neutral | $8.00 |
| 2014-10-10 | Initiated Coverage | Roth Capital | Buy | $9.00 |
| 2014-10-01 | Reiterated Rating | Wedbush | Outperform | |
| 2014-05-12 | Boost Price Target | Wedbush | Outperform | $14.00 |
| 2014-04-29 | Upgrade | MLV & Co. | Hold to Buy | $7.00 |
| 2014-03-11 | Downgrade | MLV & Co. | Buy to Hold | $8.00 to $7.00 |
| 2014-03-05 | Boost Price Target | Ladenburg Thalmann | Buy | $6.50 to $10.00 |
| 2014-03-05 | Boost Price Target | Canaccord Genuity | $8.00 to $10.00 | |
| 2014-03-05 | Downgrade | Credit Suisse | Outperform to Neutral | $8.00 to $7.00 |
| 2014-03-05 | Lower Price Target | Jefferies Group | $11.00 to $9.00 | |
| 2014-01-29 | Boost Price Target | Wedbush | $8.00 to $13.00 | |
| 2014-01-09 | Initiated Coverage | Jefferies Group | Hold to Buy | $11.00 |
| 2013-11-01 | Boost Price Target | Roth Capital | Buy | $6.00 to $8.00 |
| 2013-11-01 | Boost Price Target | Credit Suisse | Outperform | $5.00 to $8.00 |
| 2013-10-31 | Reiterated | MLV & Co | Buy | $7.50 to $8 |
| 2013-10-31 | Boost Price Target | RBC Capital | Outperform | $7.00 to $9.00 |
| 2013-10-31 | Boost Price Target | MLV & Co. | Buy | $7.50 to $8.00 |
| 2012-05-14 | Initiated | Cowen & Co | Outperform | |
| 2011-03-31 | Reiterated | MLV Capital | Buy | $12 to $10 |
| 2011-01-06 | Reiterated | Ladenburg Thalmann | Buy | $12 to $16 |
| 2016-05-05 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-03-12 | Reiterated Rating | Piper Jaffray | Hold | |
| 2016-03-12 | Reiterated Rating | Piper Jaffray Cos. | Hold | |
| 2016-03-11 | Reiterated Rating | Wedbush | Outperform | $6.00 to $3.00 |
| 2016-03-11 | Reiterated Rating | RBC Capital | Sector Perform | $2.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In XOMA 39 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BVF INC/IL | 3.61M |
| FMR LLC | 1.22M |
| Vanguard Group, Inc | 0.29M |
| Opaleye Management Inc. | 0.25M |
| BlackRock Inc. | 0.12M |
| BlackRock Institutional Trust Company, N.A. | 96695 |
| GEODE CAPITAL MANAGEMENT, LLC | 80085 |
| Stonepine Capital Management, LLC | 64459 |
| RUSSELL FRANK CO/ | 56400 |
| CITADEL ADVISORS LLC | 54050 |
| MORGAN STANLEY | 49851 |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 45089 |
| NORTHERN TRUST CORP | 42410 |
| RBF Capital, LLC | 34787 |
| STATE STREET CORP | 34574 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| RUBIN PAUL D Sr. VP Clinical Dev. & CMO | 0.31% (326601) | SGNL / XOMA / |
| Klein Thomas Chief Commercial Officer | 0.15% (158050) | XOMA / |
| VAN NESS W DENMAN | 0.13% (139596) | XOMA / |
| WYSZOMIERSKI JACK L | 0.12% (129314) | ATHX / EXEL / SITE / XOMA / |
| Walbert Timothy P | 0.12% (129314) | EGLT / HZNP / RPTP / SCMP / XOMA / |
| LIMBER JOSEPH M | 0.12% (124219) | CBMX / XOMA / |
| BAKER BROS. ADVISORS LP | 0.08% (90538) | ACAD / AQXP / BCRX / GHDX / IDRA / INCY / MRTX / SGEN / XOMA / |
| KURLAND FRED CFO & VP Finance | 0.07% (79086) | XOMA / |
| BOWES WILLIAM K JR | 0.07% (73739) | XOMA / |
| Neal James R VP Business Development | 0.02% (16333) | XOMA / |
| PERRY MATTHEW D See Explanation of Responses | 0.01% (11799) | CTIC / XOMA / |
| SCANNON PATRICK J MD PHD Exec. VP & CSO | 0.01% (8217) | PTIE / XOMA / |
| BURNS THOMAS M. VP, Finance & Chief Financial | 0.01% (6555) | XOMA / |
UM